Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells

Huensuk Kim; Christoph Schaniel

doi:10.3389/fimmu.2018.02243

Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells

Huensuk Kim, Christoph Schaniel

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The advent of induced pluripotent stem cells (iPSCs) together with recent advances in genome editing, microphysiological systems, tissue engineering and xenograft models present new opportunities for the investigation of hematological diseases and cancer in a patient-specific context. Here we review the progress in the field and discuss the advantages, limitations, and challenges of iPSC-based malignancy modeling. We will also discuss the use of iPSCs and its derivatives as cellular sources for drug target identification, drug development and evaluation of pharmacological responses.

Original language	English
Article number	2243
Journal	Frontiers in Immunology
Volume	9
DOIs	https://doi.org/10.3389/fimmu.2018.02243
State	Published - 28 Sep 2018

Keywords

blood disorders
cancer
hematopoietic malignancies
induced pluripotent stem cells
model systems

Access to Document

10.3389/fimmu.2018.02243

Cite this

@article{7f5bb5b419b14943a5f46cf8cd0021b4,

title = "Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells",

abstract = "The advent of induced pluripotent stem cells (iPSCs) together with recent advances in genome editing, microphysiological systems, tissue engineering and xenograft models present new opportunities for the investigation of hematological diseases and cancer in a patient-specific context. Here we review the progress in the field and discuss the advantages, limitations, and challenges of iPSC-based malignancy modeling. We will also discuss the use of iPSCs and its derivatives as cellular sources for drug target identification, drug development and evaluation of pharmacological responses.",

keywords = "blood disorders, cancer, hematopoietic malignancies, induced pluripotent stem cells, model systems",

author = "Huensuk Kim and Christoph Schaniel",

note = "Funding Information: The authors wish to acknowledge the late Ihor R. Lemischka for his support and mentorship over the years. HK is the recipient of an NCI Pre- to Post-doctoral Transition Award (1F99CA212489). Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2018 Kim and Schaniel.",

year = "2018",

month = sep,

day = "28",

doi = "10.3389/fimmu.2018.02243",

language = "English",

volume = "9",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells

AU - Kim, Huensuk

AU - Schaniel, Christoph

N1 - Funding Information: The authors wish to acknowledge the late Ihor R. Lemischka for his support and mentorship over the years. HK is the recipient of an NCI Pre- to Post-doctoral Transition Award (1F99CA212489). Publisher Copyright: © Copyright © 2018 Kim and Schaniel.

PY - 2018/9/28

Y1 - 2018/9/28

N2 - The advent of induced pluripotent stem cells (iPSCs) together with recent advances in genome editing, microphysiological systems, tissue engineering and xenograft models present new opportunities for the investigation of hematological diseases and cancer in a patient-specific context. Here we review the progress in the field and discuss the advantages, limitations, and challenges of iPSC-based malignancy modeling. We will also discuss the use of iPSCs and its derivatives as cellular sources for drug target identification, drug development and evaluation of pharmacological responses.

AB - The advent of induced pluripotent stem cells (iPSCs) together with recent advances in genome editing, microphysiological systems, tissue engineering and xenograft models present new opportunities for the investigation of hematological diseases and cancer in a patient-specific context. Here we review the progress in the field and discuss the advantages, limitations, and challenges of iPSC-based malignancy modeling. We will also discuss the use of iPSCs and its derivatives as cellular sources for drug target identification, drug development and evaluation of pharmacological responses.

KW - blood disorders

KW - cancer

KW - hematopoietic malignancies

KW - induced pluripotent stem cells

KW - model systems

UR - http://www.scopus.com/inward/record.url?scp=85054895081&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.02243

DO - 10.3389/fimmu.2018.02243

M3 - Review article

C2 - 30323816

AN - SCOPUS:85054895081

SN - 1664-3224

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 2243

ER -

Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells

Abstract

Keywords

Access to Document

Fingerprint

Cite this